Neurocrine Biosciences Inc (NBIX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 332,100 | 213,900 | 101,400 | 106,700 | 46,500 |
| Revenue | US$ in thousands | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 | 756,124 |
| Pretax margin | 17.63% | 15.15% | 9.15% | 10.73% | 6.15% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $332,100K ÷ $1,883,200K
= 17.63%
The pretax margin of Neurocrine Biosciences, Inc. has been exhibiting a positive trend over the past five years, increasing from 5.91% in 2019 to 17.60% in 2023. This indicates that the company has been effectively managing its operating expenses and generating higher earnings before taxes in relation to its revenue. The consistent improvement in the pretax margin reflects increasing operational efficiency and profitability, which is a positive indicator for stakeholders. The company's ability to sustain and enhance its pretax margin over the years suggests sound financial management and operational performance.
Peer comparison
Dec 31, 2023